Pectin and Centella Asiatica Composition for Selective Anti-Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cosmetic and pharmaceutical compositions for reducing microorganism adhesion to skin surfaces often lack specificity, targeting both pathogenic and resident flora, and may cause imbalances in the skin's microbial ecosystem, with limited effectiveness and potential resistance issues, particularly in hospital settings and for conditions like bedsores and ischemic lesions.
Innovation Solution
A topical composition combining pectin and an extract of Centella asiatica, which exhibits a synergistic effect in reducing microorganism adhesion, providing up to 96% inhibition at specific concentrations, while maintaining the skin's natural flora balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics or bactericides are used to combat microorganisms, then the effectiveness against pathogenic flora is improved, but the specificity deteriorates as both pathogenic and resident flora are targeted indiscriminately
Solution Approach 1:
The patent changes the chemical parameters of the anti-adhesion agent from conventional antibiotics/bactericides to a specific carbohydrate structure (degree of polymerization DP3-7, specific monosaccharide composition). This parameter change enables selective interference with pathogenic bacteria adhesion mechanisms without affecting resident flora, achieving both high effectiveness and specificity
Solution Approach 2:
The invention applies a locally optimized carbohydrate composition tailored to interfere specifically with pathogenic bacteria adhesion. The specific ratio of monosaccharides and polymerization degree creates a localized effect on pathogenic flora adhesion without broadly impacting the entire microbial ecosystem
2Reliability
If antiseptics are used on chronic wounds, then the reduction of microorganism adhesion is improved, but the skin ecosystem balance deteriorates
Solution Approach 1:
The patent employs a biodegradable carbohydrate-based anti-adhesion agent that acts temporarily to prevent pathogenic bacteria adhesion during the critical wound healing phase. The agent is naturally metabolized and does not persist in the wound ecosystem, allowing restoration of natural flora balance after the protective period
Solution Approach 2:
The carbohydrate compound serves as an intermediary substance that mediates between the wound surface and pathogenic bacteria. It creates a temporary protective barrier that prevents adhesion without directly killing microorganisms, thus avoiding disruption to the wound ecosystem while providing effective protection
3Adaptability or versatility
If conventional carbohydrates are used to prevent microorganism adhesion, then the natural origin advantage is improved, but the effectiveness deteriorates
Solution Approach 1:
The patent optimizes the carbohydrate structure by controlling the degree of polymerization (DP3-7), monosaccharide composition ratios, and molecular weight distribution. These parameter optimizations enhance the anti-adhesion effectiveness of the natural carbohydrate while maintaining its biocompatibility and natural origin advantages
Solution Approach 2:
The invention creates a composite carbohydrate structure combining multiple monosaccharide units in specific ratios with controlled polymerization degrees. This composite natural polymer achieves superior anti-adhesion effectiveness compared to single-carbohydrate molecules, while remaining of natural origin
Data Source
Figure 1
AI summary
The present invention relates to a cosmetic or pharmaceutical composition for topical application comprising, in a cosmetically or pharmaceutically acceptable medium, a combination of pectin (E440) and an extract of Centella asiatica, to the use of such a composition to prevent or reduce the adhesion of microorganisms to the surface of the skin and/or mucous membranes, to a non-therapeutic cosmetic skin care process employing such a cosmetic composition, and to the use of such a pharmaceutical composition in the prevention and/or treatment of skin lesions, and in particular in the prevention and/or treatment of bedsores and ischemic lesions.